Drug & intervention

venetoclax

RxCUI 1747556

Clinical trials13
Recruiting3
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

13 shown
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsNCT07713732 · 2026-08-05
RECRUITING
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)NCT07481175 · 2026-04-13
RECRUITING
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ARTNCT05668026 · 2024-04-01
RECRUITING
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT04298918 · 2020-09-23
TERMINATED
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).NCT04422210 · 2020-09-22
TERMINATED
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionNCT04274907 · 2020-06-30
TERMINATED
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor TherapyNCT04274933 · 2020-05-21
TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerNCT03900884 · 2019-09-25
ACTIVE_NOT_RECRUITING
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate CancerNCT03751436 · 2019-08-02
COMPLETED
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyNCT03584009 · 2018-09-06
TERMINATED
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsNCT03000257 · 2016-12-14
COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerNCT02391480 · 2015-04-14
COMPLETED

Conditions being studied

Breast Cancer3Cancer3Castration-Resistant Prostate Carcinoma2Small Cell Lung Cancer2Stage IV Prostate Cancer AJCC v82Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Acute Myeloid Leukemia (AML)1Advanced Solid Tumors1Anatomic Stage IV Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Breast Neoplasm Female1Castration Levels of Testosterone1Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.